Skip to main content
TipRanks
Go Ultimate75% OFF

Tonix Pharma (TPM0) Stock Price & Analysis

9 Followers

TPM0 Stock Chart & Stats

€2.47€0.12(5.03%)
At close: 5:30 PM GMT+1
€2.5€3€3.5€4Nov 6Nov 9Nov 16
Day’s Range
EUR 2.47 - EUR 2.47
52-Week Range
EUR 2.32 - EUR 17.00
Previous Close
EUR 2.35
Volume
N/A
Average Volume (3M)
4
Market Cap
EUR 45.16M
Enterprise Value
EUR 18.07M
Total Cash (Recent Filing)
EUR 162.79K
Total Debt (Recent Filing)
EUR 1,253
Price to Earnings (P/E)
―
Beta
0.49
Next Earnings
Mar 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth And High Gross Margin

TTM revenue rose from $13.1M in 2025 to $43.0M, while gross margin reached about 86.9%. This combination shows TONMYA-driven commercialization is adding meaningful scale and leaves substantial gross profit per dollar of sales, creating a platform for future operating leverage if growth persists.

TONMYA Commercial Traction

TONMYA has demonstrated repeatable commercial adoption: Q3 sales grew 37% QoQ, prescriptions 28%, and refills 56%, while coverage reached 53% of covered lives. Expanding payer access and prescriber reach can support recurring demand and improve the product’s durability beyond an initial launch spike.

Advancing Clinical Pipeline

FDA agreement on the adaptive Phase II TNX-4800 design, planned enrollment of about 3,300 adults, and manufacturing and CRO preparation establish a defined path for a significant clinical program. This advances pipeline diversification and preserves longer-term upside beyond TONMYA.

Bears Say

Severe Operating Losses And Cash Burn

TTM EBIT was -$187.8M, operating cash flow -$165.3M, and free cash flow -$170.0M. Persistent losses at this scale consume resources despite revenue growth, reduce internally funded investment capacity, and make continued external financing important for sustaining development and commercialization.

TONMYA Patent Litigation Risk

Dr. Reddy’s Paragraph IV filing challenges four TONMYA patents, forcing Tonix into litigation to defend the branded franchise. Although the complaint triggered a potential 30-month stay, the dispute creates durable uncertainty around exclusivity, future competition, and the value of TONMYA’s revenue stream.

Elevated Commercialization Costs

SG&A increased sharply to $45.6M from $25.7M, and management expects the sales force to remain a significant cost as TONMYA expands. These elevated commercialization expenses can delay operating leverage and intensify cash consumption if revenue growth does not outpace launch spending.

Tonix Pharma News

TPM0 FAQ

What was Tonix Pharma’s price range in the past 12 months?
Tonix Pharma lowest stock price was €2.32 and its highest was €17.00 in the past 12 months.
What is Tonix Pharma’s market cap?
Tonix Pharma’s market cap is €45.16M.
When is Tonix Pharma’s upcoming earnings report date?
Tonix Pharma’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 114 days.
How were Tonix Pharma’s earnings last quarter?
Tonix Pharma released its earnings results on Nov 09, 2026. The company reported -€2.629 earnings per share for the quarter, missing the consensus estimate of -€2.173 by -€0.456.
Is Tonix Pharma overvalued?
According to Wall Street analysts Tonix Pharma’s price is currently Undervalued.
Does Tonix Pharma pay dividends?
Tonix Pharma does not currently pay dividends.
What is Tonix Pharma’s EPS estimate?
Tonix Pharma’s EPS estimate is -2.33.
How many shares outstanding does Tonix Pharma have?
Tonix Pharma has 19,431,517 shares outstanding.
What happened to Tonix Pharma’s price movement after its last earnings report?
Tonix Pharma reported an EPS of -€2.629 in its last earnings report, missing expectations of -€2.173. Following the earnings report the stock price went down -6.479%.
Which hedge fund is a major shareholder of Tonix Pharma?
Currently, no hedge funds are holding shares in DE:TPM0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology